What were the key scientific hypotheses and mechanistic insights that shaped the discovery of Nerandomilast, and how was its target pathway prioritized for development?

• Which preclinical models, assays, and biomarkerscwere instrumental in demonstrating early efficacy and translatability? What differentiated these findings from past failures in the field?
• How did the integration of pharmacodynamic data, toxicology, and translational biomarkers enable informed decisionmaking and de-risk progression into clinical trials?